Build status - In Progress

A Randomized Double-Blind Placebo-Controlled Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab Ramucirumab and Paclitaxel in Subjects With Previously Treated Locally-Advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)

A Randomized Double-Blind Placebo-Controlled Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab Ramucirumab and Paclitaxel in Subjects With Previously Treated Locally-Advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Recruiting
19 years - 99 years
All
Phase N/A
10 participants needed
1 Location

Brief description of study

This study is being done to see if tucatinib with trastuzumab, ramucirumab and paclitaxel works better than ramucirumab and paclitaxel to treat HER2-positive (HER2+) cancer of the gut (stomach or gastroesophageal cancer). This study will also look at what side effects happen when participants take this combination of drugs

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 19 years - 99 years
  • Gender: All

Male and Female over 18 years of age

Updated on 04 Aug 2024. Study ID: 844367

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center